The percutaneous closure of patent foramen ovale (PFO): Impact on the quality of life

Evola, Salvatore; Kauroo, B.A. Waseem; Trovato, Rosaria Linda; Alioto, L.; D'Amico, Giovanni; Fonte, Giuseppe; Andolina, Giuseppe; Novo, Salvatore; Assennato, Pasquale

doi:10.1016/j.ijcard.2013.01.015

Cited by 11 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mirzada N [ 17 ] explained that the prospect of effective secondary prevention of ischemic recurrences could certainly contribute to better physical, mental, and social functioning in patients who undergo PFO closure. Results reported by Evola S [ 18 ] indicated a reasonable association with improvement of migraines, due to a reduction in the frequency and severity of migraine attacks. Lelakowska M [ 19 ] also reported that the utility score value of the SF-36 total score was markedly higher 6 months after PFO closure compared with pre-PFO closure.…”

Section: Methodsmentioning

confidence: 94%

Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke

et al. 2022

View full text Add to dashboard Cite

Background Closure of a patent foramen ovale reduces the risk of recurrent stroke compared with medical therapy alone in young patients with cryptogenic strokes revealed by randomized control trials. Some cost-effectiveness analyses outside Japan have shown that patent foramen ovale closure is cost-effective, but no studies have examined cost-effectiveness in Japan. The objective of this study is to assess cost-effectiveness, from the perspective of a Japanese healthcare payer, of patent foramen ovale closure versus medical therapy alone for patients with patent foramen ovale related to cryptogenic strokes. Methods A cost-effectiveness study was conducted by developing a decision tree and a Markov model. Probabilities and a 5.9-year time horizon followed the RESPECT study. Utilities and costs were based upon published studies and assumptions. All assumptions were assessed by experts, including a cardiologist and a statistical expert. The target population comprised patients with cryptogenic stroke and patent foramen ovale, aged 60 years or younger. The model was discounted at 2.0% and its cycle was one month. A willingness-to-pay threshold is set at $50,000 / quality-adjusted life years (QALYs). Incremental cost-effectiveness ratio was evaluated. Then one-way sensitivity analyses as deterministic sensitivity analysis, and probabilistic sensitivity analyses were performed to assess data robustness. Results Incremental quality-adjusted life years, incremental costs, and incremental cost-effectiveness ratio were 0.464, $13,562, and $29,208 per QALY gained, respectively. One-way sensitivity analysis showed that the stable state utility score difference between patent foramen ovale closure and medical therapy had the largest impact on incremental cost-effectiveness ratio. Patent foramen ovale closure is cost-effective at a stable state utility score difference of >0.051, compared with medical therapy. Probabilistic sensitivity analyses demonstrated that patent foramen ovale closure was 50.3% cost-effective. Conclusions Patent foramen ovale closure was cost-effective compared with medical therapy for Japanese patients with cryptogenic stroke who were ≤60 years.

show abstract

Section: Methodsmentioning

confidence: 94%

Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Increasing evidence suggests that the role of infective endocarditis antibiotic prophylaxis remains a dark side of the cardio-oncology prevention [1,11,12] as well as the role of the thromboembolism prophylaxis [19]. Certain congenital cardiac defects may go undetected for several years due to lack of symptoms and signs [36][37][38][39][40][41][42][43][44][45][46][47]. We present a case of a chance finding of an important atrial septal defect in a 73-year-old Italian woman evaluated for an oncosurgery intervention.…”

mentioning

confidence: 99%